Cilostazol induced migraine does not respond to sumatriptan in a double blind trial

BACKGROUND: Cilostazol is an inhibitor of phosphodiesterase 3 and thus causes accumulation of cAMP. It induces migraine-like attacks in migraine patients. Whether the cilostazol model responds to sumatriptan in migraine patients and therefore is valid for testing of future anti-migraine medications...

Descripción completa

Detalles Bibliográficos
Autores principales: Falkenberg, Katrine, Dunga, Bára Óladóttir á, Guo, Song, Ashina, Messoud, Olesen, Jes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796931/
https://www.ncbi.nlm.nih.gov/pubmed/29396788
http://dx.doi.org/10.1186/s10194-018-0841-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796931/
https://www.ncbi.nlm.nih.gov/pubmed/29396788
http://dx.doi.org/10.1186/s10194-018-0841-7

Ejemplares similares